Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dorocubicel→

Dorocubicel Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2655472-00-5
Molecular formula
Not available
Molecular weight
Not available
Drug class
Expanded allogeneic umbilical-cord-blood haematopoietic stem-cell productinvestigational cell therapy
Mechanism of action
An ex-vivo expanded cord-blood cell product intended to increase the number of transplantable haematopoietic progenitor cells and support engraftment after allogeneic transplantation. The therapeutic effect is mediated by donor-derived haematopoietic reconstitution rather than a conventional drug-receptor mechanism.
Indications / reported uses
  • Investigated as an alternative donor haematopoietic stem-cell source for patients requiring allogeneic transplantation who lack a suitable matched donor; no current general marketing-authorisation indication should be assigned without confirming jurisdiction-specific approval

Sources: ClinicalTrials.gov — Dorocubicel studies · PubMed — Expanded cord blood cell transplantation · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dorocubicel Environmental Risk Assessment (ERA) (the Dorocubicel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.